One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133⁺ Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction

Abstract

Bone marrow stem cell therapy has emerged as a promising approach to improve healing of the infarcted myocardium. Despite initial excitement, recent clinical trials using non-homogenous stem cells preparations showed variable and mixed results. Selected CD133+ hematopoietic stem cells are candidate cells with high potential. Herein, we report the one-year safety analysis on the initial 20 patients enrolled in the COMPARE-AMI trial, the first double-blind randomized controlled trial comparing the safety, efficacy, and functional effect of intracoronary injection of selected CD133+ cells to placebo following acute myocardial infarction with persistent left ventricular dysfunction. At one year, there is no protocol-related complication to report such as death, myocardial infarction, stroke, or sustained ventricular arrhythmia. In addition, the left ventricular ejection fraction significantly improved at four months as compared to baseline and remained significantly higher at one year. These data indicate that in the setting of the COMPARE-AMI trial, the intracoronary injection of selected CD133+ stem cells is secure and feasible in patients with left ventricle dysfunction following acute myocardial infarction.

Long Term Clinical Results of Autologous Cd133+ Bone Marrow Cells Transplantation in St Elevation Myocardial Infarction Patients

“…В единичных работах для трансплантации при ОИМ использовалась популяция CD133 + ККМ [2,5,9,10]. Как известно, антиген CD133 + экспрессиру-ется на незрелых гемопоэтических и прогениторных клетках.…”

Quality Control for Mesenchymal Stromal Cells: Chondrogenesis as a Standard Condition?

“…With the first attempts to introduce MSCs in regenerative treatment patterns, perhaps most spectacularly in heart diseases [19,20], the issue of uniform standardization has gained more and more attention. Oversight agencies have drafted legal frameworks and definitions (TEMP = tissue engineered medicinal products (USA), ATMP = advanced therapies medicinal products (EU)) but their conversion into measurable methodology still remains to be implemented.…”

Methods to improve cardiac gene therapy expression

“…Additionally, directing cells to the target area also presents a problem which researchers must identify to initiate viable clinical studies. As a result, few clinical trials of stem cell therapies have been conducted [48,36,49,50], and the only common stem cell-based therapy in practice is currently bone marrow transplantation and cardiac stem cells.…”